Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medirom Healthcare Technologies (MRM) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Medirom Healthcare Technologies (MRM) over the last 6 years, with Q2 2025 value amounting to $225737.5.

  • Medirom Healthcare Technologies' Cash & Equivalents fell 6695.7% to $225737.5 in Q2 2025 from the same period last year, while for Jun 2025 it was $225737.5, marking a year-over-year decrease of 6695.7%. This contributed to the annual value of $2.2 million for FY2024, which is 4710.22% down from last year.
  • Medirom Healthcare Technologies' Cash & Equivalents amounted to $225737.5 in Q2 2025, which was down 6695.7% from $2.2 million recorded in Q4 2024.
  • Medirom Healthcare Technologies' Cash & Equivalents' 5-year high stood at $13.2 million during Q2 2021, with a 5-year trough of $225737.5 in Q2 2025.
  • Its 5-year average for Cash & Equivalents is $3.7 million, with a median of $2.9 million in 2022.
  • As far as peak fluctuations go, Medirom Healthcare Technologies' Cash & Equivalents skyrocketed by 17539.65% in 2021, and later plummeted by 8453.67% in 2024.
  • Medirom Healthcare Technologies' Cash & Equivalents (Quarter) stood at $3.3 million in 2021, then decreased by 19.54% to $2.6 million in 2022, then skyrocketed by 56.14% to $4.1 million in 2023, then crashed by 47.1% to $2.2 million in 2024, then tumbled by 89.58% to $225737.5 in 2025.
  • Its Cash & Equivalents stands at $225737.5 for Q2 2025, versus $2.2 million for Q4 2024 and $683162.4 for Q2 2024.